herp
simplex
viru
type
widespread
human
pathogen
caus
sever
diseas
effect
safe
drug
clinic
therapi
besid
acyclovir
acv
relat
nucleosid
analog
studi
two
new
venom
peptid
scorpion
heterometru
petersii
identifi
effect
inhibitori
effect
infect
vitro
peptid
exhibit
potent
virucid
activ
ec
lm
respect
effect
inhibitori
effect
ad
viral
attach
ec
lm
respect
entri
ec
lm
respect
postentri
ec
lm
respect
step
peptid
adopt
ahelix
structur
approxim
membran
environ
result
destruct
viral
morpholog
moreov
peptid
enter
vero
cell
reduc
intracellular
viral
infect
taken
togeth
peptid
two
antivir
peptid
effect
inhibitori
effect
multipl
step
life
cycl
therefor
good
candid
develop
virucid
herp
simplex
viru
type
widespread
human
pathogen
infect
primarili
epitheli
tissu
caus
sever
diseas
includ
mucocutan
lesion
oral
mucosa
cold
sore
enceph
mening
blind
kerat
gopinath
et
al
initi
infect
spread
nervou
system
establish
latent
infect
neuron
sensori
ganglia
host
hill
et
al
approxim
world
popul
carrier
suffer
recurr
infect
gold
corey
palem
et
al
current
therapeut
drug
hsv
infect
nucleotid
nucleosid
pyrophosph
analogu
acyclovir
valacyclovir
penciclovir
famciclovir
hsiang
ho
uptak
virusinfect
cell
drug
activ
viral
thymidin
kinas
inhibit
viral
dna
polymeras
howev
hsv
infect
remain
seriou
challeng
viral
resist
side
effect
crute
et
al
field
therefor
develop
new
safe
effect
antihsv
molecul
urgent
need
mani
antimicrobi
peptid
amp
shown
inhibitori
activ
hsv
infect
accord
structur
characterist
peptid
classifi
five
type
ahelix
bsheet
cyclic
bsheet
bturn
extend
jenssen
et
al
propos
antivir
mechan
ahelix
mainli
includ
cellular
target
viral
inactiv
includ
magainin
cecropin
mellitin
aboudi
et
al
albiol
matan
castilla
yasin
et
al
two
kind
bsheet
peptid
human
rabbit
defensin
shown
interact
hsv
membraneglycoprotein
cellular
target
heparan
sulfat
sinha
et
al
yasin
et
al
anoth
bsheet
peptid
frog
dermaseptin
shown
potent
inhibitori
effect
appli
viru
viru
adsorpt
target
cell
belaid
et
al
two
bsheet
peptid
tachyplesin
protegrin
prove
viral
inactiv
effect
yasin
et
al
cyclic
bsheet
peptid
hdefensin
shown
bound
gb
protein
block
attach
yasin
et
al
bturn
peptid
lactoferrin
lf
lactoferricin
lfcin
antimicrobi
peptid
found
block
hsv
entri
vero
cell
lf
effect
hsv
viru
enter
cell
lfcin
exert
antivir
activ
also
initi
bind
viru
host
cell
jenssen
et
al
extend
peptid
bovin
indolicidin
show
direct
inactiv
effect
cellfre
viron
target
viral
membran
glycoprotein
albiol
matan
castilla
natur
amp
scorpion
venom
attract
much
attent
due
antivir
bioactiv
identifi
antienvelop
viru
agent
previou
work
peptid
shown
virucid
measl
sarscov
influenza
virus
inhibit
hbv
replic
vitro
vivo
zhao
et
al
natur
ahel
peptid
proven
properti
kill
hcv
two
histidin
rich
peptid
design
molecular
templat
short
virucid
peptid
confirm
enhanc
bioavail
result
potent
inhibitori
effect
hcv
prolifer
hong
et
al
anoth
mutat
peptid
also
effect
inhibit
infect
chen
et
al
studi
indic
scorpion
venom
rich
sourc
antivir
peptid
present
studi
screen
identifi
two
peptid
venom
scorpion
heterometru
petersii
exhibit
effect
inhibitori
effect
infect
peptid
nonamplifi
cdna
librari
h
petersii
venom
gland
construct
previou
work
et
al
peptid
chemic
synthes
use
solidphas
synthesi
method
amid
cterminu
gl
biochem
ltd
china
synthet
peptid
confirm
rphplc
malditofm
puriti
african
green
monkey
kidney
cell
vero
grown
minimum
essenti
medium
mem
supplement
volvol
fetal
bovin
serum
fb
uml
penicillin
lgml
streptomycin
sulfat
co
incub
cell
infect
viru
grown
mem
supplement
serum
prepar
hightit
stock
f
strain
viru
vero
cell
infect
low
multipl
infect
moi
flask
nest
biotechnolog
co
ltd
china
cytopath
effect
cpe
infect
monolay
harvest
subject
three
freezethaw
cycl
use
dri
iceethanol
bath
centrifug
min
remov
debri
store
viral
titer
determin
plaqu
form
assay
vero
cell
cell
seed
plate
cell
per
well
cultur
h
seri
concentr
peptid
ad
medium
plate
incub
h
time
mtt
solut
mgml
pb
buffer
invitrogen
ad
well
plate
incub
h
medium
remov
dmso
ad
plate
shaken
min
room
temperatur
complet
dissolv
crystal
purpl
formazan
absorb
measur
nm
freshli
obtain
human
red
blood
cell
wash
three
time
hepe
buffer
ph
centrifug
min
cell
resuspend
salin
seed
plate
cell
per
well
seri
concentr
peptid
ad
incub
h
salin
solut
use
neg
control
triton
use
posit
control
plate
centrifug
min
absorb
hemoglobin
releas
supernat
measur
nm
sixwel
plate
contain
vero
cell
monolay
confluenc
infect
viru
h
absorpt
inocula
remov
cell
wash
three
time
phosphatebuff
salin
pb
replenish
mainten
cover
layer
mem
fb
carboxymethylcellulos
incub
period
day
cell
stain
crystal
violet
contain
methan
plaqu
count
viral
titer
calcul
accord
plaqu
number
dilut
sixwel
plate
contain
vero
cell
monolay
confluenc
infect
viru
yield
plaqu
per
well
antivir
effect
peptid
determin
follow
assay
peptid
appoint
concentr
incub
viru
indic
condit
indic
time
viruspeptid
mixtur
dilut
ad
vero
cell
monolay
h
absorpt
inocula
remov
cell
rins
replenish
cover
layer
describ
day
inhibitori
effect
determin
plaqu
reduct
assay
vero
cell
incub
peptid
h
time
peptid
remov
cell
wash
pb
three
time
peptidetr
cell
infect
viru
h
cell
rins
replenish
cover
layer
describ
day
inhibitori
effect
determin
plaqu
reduct
assay
vero
cell
cool
min
peptid
ad
vero
cell
togeth
viru
h
indic
time
cell
rins
pb
three
time
shift
viral
entri
h
incub
cell
rins
replenish
cover
layer
describ
day
inhibitori
effect
determin
plaqu
reduct
assay
vero
cell
infect
viru
h
time
cell
rins
pb
three
time
replenish
complet
mem
contain
peptid
cell
shift
viral
entri
h
incub
cell
rins
replenish
cover
layer
describ
day
inhibitori
effect
determin
plaqu
reduct
assay
vero
cell
infect
viru
h
time
cell
rins
pb
three
time
replenish
cover
layer
contain
peptid
day
inhibitori
effect
determin
plaqu
reduct
assay
secondari
structur
peptid
measur
circular
dichroism
cd
spectroscopi
measur
perform
uv
rang
nm
water
tfe
use
spectropolarimet
concentr
mgml
spectra
collect
three
separ
record
averag
subtract
blank
spectrum
pure
water
larg
quantiti
supernat
prepar
clear
differenti
centrifug
method
pass
filter
unit
viral
particl
media
concentr
ultracentrifug
rpm
h
beckman
rotor
obtain
pellet
dissolv
pb
subsequ
studi
viru
treat
peptid
incub
sampl
place
form
varcarbonco
copper
grid
dip
grid
viru
sampl
solut
sampl
neg
stain
place
drop
phosphotungst
acid
ph
adjust
naoh
grid
sampl
grid
dri
air
approxim
min
final
variou
area
grid
examin
photograph
taken
hitachi
transmiss
electron
microscop
oper
kv
nterminu
fitclabel
peptid
ad
cell
final
concentr
lm
incub
incub
indic
time
cell
wash
pb
fix
paraformaldehyd
wash
twice
cell
nuclei
stain
dapi
dilut
pb
cell
rins
pb
three
time
cellular
local
peptid
analyz
confoc
microscopi
vero
cell
infect
moi
h
time
cell
rins
pb
three
time
replenish
medium
contain
peptid
infect
cell
harvest
h
postinfect
intracellular
virus
freezethaw
method
intracellular
infect
determin
plaqu
form
assay
data
express
mean
standard
deviat
least
three
separ
experi
sequenc
align
peptid
perform
use
genedoc
softwar
fig
show
typic
charact
cation
host
defens
peptid
activ
scorpion
venom
peptid
determin
plaqu
reduct
assay
pra
fig
result
show
among
six
peptid
exhibit
effect
antivir
activ
could
significantli
inhibit
plaqu
form
unit
pfu
inhibit
rate
concentr
lm
fig
result
indic
potenti
agent
chosen
studi
cytotox
peptid
vero
cell
determin
use
mtt
assay
concentr
inhibit
cell
growth
cc
lm
respect
concentr
lm
viabil
peptidetr
vero
cell
greater
indic
lm
less
peptid
use
infect
cell
h
viruspeptid
mixtur
remov
cell
rins
replenish
cover
layer
without
peptid
ii
cell
inactiv
assay
peptid
ad
cell
h
peptidetr
cell
rins
viru
infect
iii
viral
attach
assay
cell
precool
min
peptid
ad
togeth
viru
h
indic
time
cell
rins
shift
viral
entri
iv
viral
entri
assay
viru
attach
cell
h
cell
rins
peptid
ad
cultur
shift
viral
entri
v
postentri
assay
cell
infect
viru
h
time
viru
remov
cell
rins
replenish
cover
layer
contain
peptid
throughout
experi
b
c
antivir
activ
peptid
time
addit
assay
h
postinfect
cell
replenish
cover
layer
cultur
h
time
inhibitori
effect
peptid
determin
plaqu
reduct
assay
minim
cytotox
vero
cell
fig
thu
peptid
concentr
chosen
antivir
studi
hemolyt
assay
indic
hc
peptid
lm
respect
fig
sinc
shown
inhibit
plaqu
form
unit
fig
vitro
sought
determin
exact
step
block
two
peptid
determin
whether
could
inhibit
infect
replic
vero
cell
lm
peptid
ad
viru
cell
differ
time
rel
incub
fig
shown
fig
c
exhibit
potent
inhibitori
activ
ad
viru
infect
ad
cell
togeth
viral
attach
entri
step
suggest
initi
inhibitori
effect
viral
infect
contrast
display
less
inhibitori
activ
ad
cell
h
viral
infect
much
less
inhibitori
activ
ad
cell
h
remov
viru
ad
result
suggest
peptid
could
potent
inhibit
initi
infect
less
inhibitori
activ
viral
replic
result
suggest
peptid
potent
inhibitori
activ
initi
viral
infect
determin
detail
viral
inactiv
activ
inhibitori
activ
infect
timedepend
concentr
lm
fig
b
treat
min
pfu
decreas
suggest
rapid
viral
inactiv
effect
treat
h
inhibitori
activ
effect
condit
inhibitori
effect
infect
doseand
temperaturedepend
fig
effect
temperatur
treat
h
effect
concentr
ec
lm
approxim
lower
cc
vero
cell
respect
tabl
variou
concentr
peptid
ad
vero
cell
h
infect
inhibitori
effect
determin
plaqu
assay
shown
fig
slightli
inhibit
infect
preincub
vero
cell
addit
peptid
inhibit
attach
entri
dosedepend
manner
although
weaker
virucid
activ
viral
attach
assay
effect
ec
concentr
lm
respect
fig
approxim
lower
cc
vero
cell
viral
entri
assay
effect
ec
concentr
lm
respect
fig
final
ad
h
postinfect
inhibit
prolifer
ec
lm
respect
fig
pharmacolog
profil
peptid
list
tabl
circular
dichroism
cd
analysi
use
analyz
secondari
structur
peptid
result
show
synthet
peptid
exhibit
ahelix
structur
tfe
fig
c
plot
helic
wheel
project
fig
divid
two
part
one
part
hydrophob
face
hydrophil
face
data
indic
amphipath
peptid
molecul
confirm
whether
viral
structur
integr
destabil
treatment
perform
transmiss
electron
microscopi
tem
experi
monitor
morpholog
chang
shown
fig
morpholog
untreat
virion
mostli
integr
contain
compact
envelop
nm
treatment
either
significantli
chang
structur
includ
ruptur
viral
envelop
dissoci
protein
viron
gener
display
incompact
morpholog
result
strongli
support
underli
mechan
action
destabil
integr
inhibit
infect
explor
intracellular
antivir
mechan
confoc
microscopi
use
investig
whether
peptid
could
penetr
cell
membran
enter
vero
cell
shown
fig
c
fitclabel
peptid
slightli
enter
vero
cell
accumul
granular
structur
cytoplasm
incub
h
howev
exhibit
higher
amount
cellular
uptak
incub
h
dispers
distribut
cytoplasm
moreov
infect
cell
incub
h
infect
intracellular
viru
significantli
decreas
fig
result
suggest
peptid
enter
vero
cell
inactiv
intracellular
viral
particl
current
variou
virucid
agent
identifi
provid
rich
sourc
develop
effect
antivir
drug
challeng
solv
lack
inhibitori
effect
viral
postentri
step
inhibit
celltocel
spread
import
topic
microbicid
develop
sourc
sexual
acquisit
also
may
cellassoci
viru
sinha
et
al
deriv
virucid
peptid
disturb
integr
viral
membran
exhibit
potent
virucid
activ
hcv
worth
mention
properti
suppress
viral
entri
establish
infect
differ
common
virucid
agent
bobardt
et
al
cheng
et
al
de
witt
et
al
studi
screen
identifi
two
new
antivir
peptid
peptid
librari
scorpion
venom
peptid
potent
inhibitori
effect
prolifer
fig
select
analysi
prove
inhibit
multipl
step
life
cycl
fig
noncytotox
concentr
peptid
effect
inactiv
viron
time
doseand
temperaturedepend
manner
vitro
fig
also
block
attach
entri
vero
cell
worthi
attent
could
prevent
viral
prolifer
postentri
assay
fig
comprehens
antivir
assay
found
induc
poor
cellular
resist
infect
suggest
might
effect
target
cellular
compon
howev
display
effect
inhibitori
activ
viral
attach
entri
stage
accord
timedepend
virucid
experi
fig
b
peptid
inactiv
viru
min
min
indic
rapid
action
mode
properti
specul
may
inactiv
attach
cell
surfac
also
effect
inactiv
viru
alreadi
bound
cell
entri
yet
previou
studi
seriou
antivir
peptid
scorpion
venom
identifi
hong
et
al
yan
et
al
peptid
share
ahelix
structur
similar
virucid
activ
envelop
viru
howev
lack
inhibitori
activ
ad
cell
viral
infect
disadvantag
badli
reduc
medic
valu
type
antivir
peptid
studi
found
peptid
exhibit
potent
inhibitori
effect
prolifer
postentri
assay
obvious
differ
virucid
peptid
similar
mutant
virucid
peptid
hong
et
al
virucid
activ
mostli
depend
sequenc
structur
charact
recent
studi
shown
sialic
acid
envelop
glycoprotein
requir
effici
infect
bpeptid
possibl
bind
sialic
acid
result
inhibitori
effect
infect
akkarawongsa
et
al
teuton
brandt
studi
cd
analysi
display
peptid
adopt
amphipath
ahelix
structur
approxim
membran
environ
posit
charg
amino
acid
expos
outsid
helix
wheel
fig
therefor
specul
peptid
interact
directli
viral
membran
via
bind
neg
charg
sialic
acid
unit
viru
inactiv
viral
particl
nevertheless
futur
studi
need
identifi
target
viru
transmiss
electron
microscopi
use
monitor
morpholog
chang
adenoviru
type
show
conform
chang
viral
protein
result
destruct
viral
morpholog
yoon
et
al
present
studi
also
observ
signific
structur
chang
especi
ruptur
viral
envelop
incompact
morpholog
viron
fig
first
time
show
morpholog
chang
envelop
viru
antivir
peptid
provid
direct
reveal
mechan
virucid
drug
find
intracellular
mechan
inhibitori
effect
viral
prolifer
firstli
determin
cellular
local
shown
fig
c
fitclabel
peptid
slightli
enter
vero
cell
h
postincub
display
big
amount
uptak
equal
dispers
distribut
cytoplasm
h
moreov
inhibitori
activ
intracellular
viral
infect
fig
intracellular
matur
virion
rapidli
accumul
high
level
h
postinfect
time
intracellular
virucid
activ
significantli
reflect
thu
conclud
enter
vero
cell
target
matur
viral
particl
inactiv
previous
design
two
histidin
rich
peptid
enhanc
cellular
uptak
advanc
intracellular
distribut
result
potent
antivir
activ
hcv
hong
et
al
present
studi
found
two
natur
peptid
properti
antivir
function
indic
divers
biomolecul
scorpion
venom
mani
antivir
drug
readili
lead
gener
drugresist
viru
variant
two
decad
antivir
drug
target
viral
dna
polymeras
acyclovir
acv
wide
use
treatment
hsv
infect
unfortun
extens
clinic
use
drug
led
emerg
drugresist
viral
strain
greco
et
al
krawczyk
et
al
use
virucid
peptid
treatment
hsv
infect
gener
drugresist
viru
variant
like
reduc
amphipath
ahelix
peptid
potent
virucid
activ
inhibitori
effect
viral
prolifer
exhibit
potenti
medic
valu
treatment
viral
infect
furthermor
advantag
therapeut
allianc
antivir
strategi
becam
diversif
alreadi
achiev
remark
success
way
virucid
molecul
may
act
potenti
member
particip
therapeut
allianc
uniqu
antivir
pattern
brief
kind
membranetarget
peptid
could
combin
drug
target
intracellular
compon
viral
life
cycl
thu
virucid
peptid
use
combin
proteas
andor
polymeras
inhibitor
target
multipl
step
viral
infect
cycl
would
advantag
singl
drug
therapi
reduc
viral
titer
well
suppress
emerg
viral
resist
liu
et
al
summari
present
studi
reveal
first
time
scorpion
venom
cation
peptid
inde
effect
infect
vitro
screen
peptid
exhibit
extracellular
virucid
activ
also
potent
inhibitori
effect
ad
viral
attach
entri
step
virucid
activ
depend
morpholog
chang
viron
treatment
properti
amphipath
ahelix
conform
appropri
membran
environ
possibl
contribut
membran
penetr
virucid
activ
result
intracellular
antivir
effect
easili
enter
vero
cell
natur
peptid
also
inactiv
intracellular
viral
particl
inhibit
viral
prolifer
postinfect
step
work
provid
new
direct
develop
potenti
biofunct
molecul
anim
venom
open
new
avenu
discov
antivir
agent
sourc
